These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 22915620

  • 1. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
    Finzel S, Kraus S, Schmidt S, Hueber A, Rech J, Engelke K, Englbrecht M, Schett G.
    Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
    Chandran V, Shen H, Pollock RA, Pellett FJ, Carty A, Cook RJ, Gladman DD.
    J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
    [Abstract] [Full Text] [Related]

  • 4. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
    Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kalstad S, Rødevand E, Mikkelsen K, Lexberg AS, Kvien TK.
    Ann Rheum Dis; 2013 Nov; 72(11):1840-4. PubMed ID: 23562987
    [Abstract] [Full Text] [Related]

  • 5. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, Lapadula G.
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [Abstract] [Full Text] [Related]

  • 6. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, Kalstad S, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
    Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O.
    J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
    [Abstract] [Full Text] [Related]

  • 8. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
    Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, Kvien TK.
    Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
    Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R, ARTIS group.
    Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
    [Abstract] [Full Text] [Related]

  • 10. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK, Lunt M, Low AL, Dixon WG, Watson KD, Symmons DP, Hyrich KL, BSRBR Control Centre Consortium.
    Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
    [Abstract] [Full Text] [Related]

  • 11. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion.
    Finzel S, Rech J, Schmidt S, Engelke K, Englbrecht M, Stach C, Schett G.
    Ann Rheum Dis; 2011 Sep; 70(9):1587-93. PubMed ID: 21622765
    [Abstract] [Full Text] [Related]

  • 12. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 13. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
    Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT, ARTIS Study Group.
    Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
    [Abstract] [Full Text] [Related]

  • 14. Development of a preliminary US power Doppler composite score for monitoring treatment in PsA.
    Gutierrez M, Di Geso L, Salaffi F, Bertolazzi C, Tardella M, Filosa G, Filippucci E, Grassi W.
    Rheumatology (Oxford); 2012 Jul; 51(7):1261-8. PubMed ID: 22378715
    [Abstract] [Full Text] [Related]

  • 15. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.
    Mease PJ.
    Ann Rheum Dis; 2002 Apr; 61(4):298-304. PubMed ID: 11874829
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
    Kim YJ, Kim YG, Shim TS, Koo BS, Hong S, Lee CK, Yoo B.
    Rheumatology (Oxford); 2014 Aug; 53(8):1477-81. PubMed ID: 24681840
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Infliximab treatment in psoriatic arthritis: our experience.
    Rioda WT, Adorni G.
    Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.